Advertisement

Wiener klinische Wochenschrift

, Volume 131, Supplement 1, pp 164–168 | Cite as

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung (Update 2019)

  • Stephan RaddaEmail author
  • Matthias Bolz
  • Stefan Egger
  • Vanessa Gasser-Steiner
  • Martina Kralinger
  • Stefan Mennel
  • Christoph Scholda
  • Ulrike Stolba
  • Andreas Wedrich
  • die Netzhautkommission der Österreichischen Ophthalmologischen Gesellschaft
leitlinien für die praxis
  • 81 Downloads

Zusammenfassung

Diabetes mellitus kann diabetische Retinopathie, diabetisches Makulaödem, Optikusneuropathie, Katarakt, Sekundärglaukom und Fehlfunktionen der äußeren Augenmuskeln verursachen. Die Inzidenz dieser Spätschäden korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Die Empfehlungen der Österreichischen Diabetes Gesellschaft für Diagnose, Therapie und Nachkontrolle werden übersichtsweise und bezogen auf die jeweiligen Stadien der diabetischen Augenerkrankung präsentiert.

Schlüsselwörter

Diabetische Retinopathie Diabetisches Makulaödem Retinale Laserkoagulation Intravitreale operative Medikamentenapplikation Vitrektomie 

Diagnosis, treatment and monitoring of diabetic eye disease (Update 2019)

Summary

Diabetes mellitus can cause diabetic retinopathy, diabetic macular edema, optic neuropathy, cataract or dysfunction of the eye muscles. The incidence of these defects correlates with disease duration and quality of metabolic control. Recommendations of the Austrian Diabetes Association for diagnosis, therapeutic procedures and requirements for adequate follow-up depending on stage of diabetic eye disease are summarized.

Keywords

Diabetic retinopathy Diabetic macular edema Retinal laser photocogulation Intravitreal therapy Vitrectomy 

Notes

Interessenkonflikt

S. Radda, M. Bolz, S. Egger, V. Gasser-Steiner, M. Kralinger, S. Mennel, C. Scholda, U. Stolba und A. Wedrich geben an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117(6):815–20.PubMedGoogle Scholar
  2. 2.
    McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Exp Ophthalmol. 2001;29(2):52–8.PubMedGoogle Scholar
  3. 3.
    Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82.PubMedGoogle Scholar
  4. 4.
    Hazin R, Colyer M, Lum F, et al. Revisiting diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152(5):723–9.PubMedGoogle Scholar
  5. 5.
    Hammes H, Lemmen K. Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechs. 2002;11(Suppl 2):15–6.Google Scholar
  6. 6.
    Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15(12):1875–91.PubMedGoogle Scholar
  7. 7.
    Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275–9.PubMedGoogle Scholar
  8. 8.
    Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44(2):156–63.PubMedGoogle Scholar
  9. 9.
    Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8.PubMedGoogle Scholar
  10. 10.
    The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23(8):1084–91.PubMedCentralGoogle Scholar
  11. 11.
    The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874–86.Google Scholar
  12. 12.
    Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24(6):1053–9.PubMedGoogle Scholar
  13. 13.
    Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1–11.PubMedGoogle Scholar
  14. 14.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.PubMedCentralGoogle Scholar
  15. 15.
    Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66(4):247–53.PubMedGoogle Scholar
  16. 16.
    Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18. Invest Ophthalmol Vis Sci. 1998;39(2):233–52.PubMedGoogle Scholar
  17. 17.
    Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography—Early Treatment Diabetic Retinopathy Study report number 5. The ETDRS Research Group. Ophthalmology. 1989;96(6):746–50.PubMedGoogle Scholar
  18. 18.
    Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28(1):129–35.PubMedGoogle Scholar
  19. 19.
    Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116(5):914–20.PubMedGoogle Scholar
  20. 20.
    Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21(3):172–7.PubMedGoogle Scholar
  21. 21.
    Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49(6):2627–34.PubMedGoogle Scholar
  22. 22.
    Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145(1):149–54.PubMedGoogle Scholar
  23. 23.
    Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116(1):66–72.PubMedGoogle Scholar
  24. 24.
    Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Ophthalmology. 1991;98(Suppl 5):834–40.Google Scholar
  25. 25.
    Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19(4):285–91.PubMedGoogle Scholar
  26. 26.
    Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219(5):292–6.PubMedGoogle Scholar
  27. 27.
    The Early Treatment Diabetic Retinopathy Study Research Group. Case reports to accompany Early Treatment Diabetic Retinopathy Study reports 3 and 4. Int Ophthalmol Clin. 1987;27(4):273–333.Google Scholar
  28. 28.
    Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;5(1):823–33.Google Scholar
  29. 29.
    Lindgren G, Lindblom B. Causes of vitreous hemorrhage. Curr Opin Ophthalmol. 1996;7(3):13–9.PubMedGoogle Scholar
  30. 30.
    Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41.PubMedGoogle Scholar
  31. 31.
    Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223–32.PubMedGoogle Scholar
  32. 32.
    The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287(19):2542–51.Google Scholar
  33. 33.
    Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94(7):761–74.Google Scholar
  34. 34.
    Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18(3):178–84.PubMedGoogle Scholar
  35. 35.
    The Diabetes Control and Complications Trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995;113(1):36–51.Google Scholar
  36. 36.
    Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86(5):565–71.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80(1):19–24.PubMedGoogle Scholar
  38. 38.
    Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28(4):626–30.PubMedGoogle Scholar
  39. 39.
    Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–S50.PubMedGoogle Scholar
  40. 40.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.PubMedCentralGoogle Scholar
  41. 41.
    Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118(12):e5–e14.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51.PubMedGoogle Scholar
  44. 44.
    Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–405.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Elman MJ, Bressler NM, Qin H, et al. Expanded 2‑year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.PubMedGoogle Scholar
  47. 47.
    Elman MJ, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5‑year randomized trial results. Ophthalmology. 2015;122(2):375–81.  https://doi.org/10.1016/j.ophtha.2014.08.047.PubMedGoogle Scholar
  48. 48.
    Korobelnik JF, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54.  https://doi.org/10.1016/j.ophtha.2014.05.006.PubMedGoogle Scholar
  49. 49.
    The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203.  https://doi.org/10.1056/NEJMoa1414264.PubMedCentralGoogle Scholar
  50. 50.
    Elman MJ, Bressler NM, Qin H, et al. Expanded 2‑year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25.PubMedGoogle Scholar
  52. 52.
    Elman MJ, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5‑year randomized trial results. Ophthalmology. 2015;122(2):375–81.  https://doi.org/10.1016/j.ophtha.2014.08.047.PubMedGoogle Scholar
  53. 53.
    Boyer DS. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14.  https://doi.org/10.1016/j.ophtha.2014.04.024.PubMedGoogle Scholar
  54. 54.
    Campochiaro PA. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2.  https://doi.org/10.1016/j.ophtha.2010.12.028.PubMedGoogle Scholar
  55. 55.
    The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81(4):383–96.Google Scholar
  56. 56.
    The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report no. 3. Int Ophthalmol Clin. 1987;27(4):254–64.Google Scholar
  57. 57.
    Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009–27.PubMedGoogle Scholar
  58. 58.
    Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74(1):84–8.PubMedGoogle Scholar
  60. 60.
    Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89(7):567–72.Google Scholar
  61. 61.
    Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26(3):173–9.PubMedGoogle Scholar
  62. 62.
    Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report no. 10. Invest Ophthalmol Vis Sci. 1985;26(7):983–91.PubMedGoogle Scholar
  63. 63.
    Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43(3):217–24.PubMedGoogle Scholar
  64. 64.
    Stanga PE, Papayannis A, Tsamis E, et al. New findings in diabetic maculopathy and proliferative disease by swept-source optical coherence tomography angiography. Dev Ophthalmol. 2016;56:113–21.PubMedGoogle Scholar
  65. 65.
    De Barros Garcia J, Isaac DLC, Avila M. Diabetic retinopathy and OCT angiography: clinical findings and future perspectives. Int J Retina Vitreous. 2017;3:14.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Cao D, Yang D, Huang Z, et al. Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. Acta Diabetol. 2018;55(5):469–77.PubMedGoogle Scholar
  67. 67.
    Schreur V, Domanian A, Liefers B, et al. Morphological and topographical appearance of microaneurysms on optical coherence tomography angiography. Br J Ophthalmol. 2018;.Google Scholar
  68. 68.
    Gross JG, Glassman AR, et al. A novel treatment for proliferative diabetic retinopathy: anti-vascular endothelial growth factor therapy. JAMA Ophthalmol. 2016;134(1):13–4.  https://doi.org/10.1001/jamaophthalmol.2015.5079.PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Stephan Radda
    • 1
    Email author
  • Matthias Bolz
    • 2
  • Stefan Egger
    • 3
  • Vanessa Gasser-Steiner
    • 4
  • Martina Kralinger
    • 5
  • Stefan Mennel
    • 6
  • Christoph Scholda
    • 7
  • Ulrike Stolba
    • 8
  • Andreas Wedrich
    • 4
  • die Netzhautkommission der Österreichischen Ophthalmologischen Gesellschaft
  1. 1.Abteilung für AugenheilkundeHanusch-KrankenhausWienÖsterreich
  2. 2.Universitätsklinik für Augenheilkunde und OptometrieKepler UniversitätsklinikumLinzÖsterreich
  3. 3.Universitätsklinik für Augenheilkunde und Optometrie, UniklinikumParacelsus Medizinische PrivatuniversitätSalzburgÖsterreich
  4. 4.Universitäts-AugenklinikMedizinische Universität GrazGrazÖsterreich
  5. 5.Universitätsklinik für Augenheilkunde und OptometrieMedizinische Universität InnsbruckInnsbruckÖsterreich
  6. 6.Abteilung für AugenheilkundeLandeskrankenhaus FeldkirchFeldkirchÖsterreich
  7. 7.Universitätsklinik für Augenheilkunde und OptometrieMedizinische Universität WienWienÖsterreich
  8. 8.AugenabteilungKrankenanstalt Rudolfstiftung und SMZ Ost – DonauspitalWienÖsterreich

Personalised recommendations